文章核心观点 - 波士顿科学在新兴市场持续增长,新的监管批准有利于公司的发展 [1] - 公司在医疗器械外科(MedSurg)分部持续增加市场份额,内窥镜业务和泌尿科业务表现良好 [2] - 神经调节业务的疼痛业务持续增长,得益于脊髓刺激系统(SCS)的创新产品组合 [3] - 公司在美国以外的地区持续成功拓展业务,2023年41%的收入来自国际市场 [4] - 公司正在加大在新兴市场的投入,这些市场增长潜力强劲 [5] - 公司在欧洲、中东和非洲(EMEA)地区也在成功拓展业务,多个业务部门表现良好 [6] - 但宏观经济环境的挑战,如地缘政治压力、供应链和劳动力市场的中断,给公司的盈利能力带来压力 [7][8] 根据目录分类总结 新兴市场拓展 - 公司在新兴市场持续增长,新的监管批准有利于公司发展 [1] - 公司正在加大在新兴市场的投入,这些市场增长潜力强劲 [5] 业务部门表现 - 公司在医疗器械外科(MedSurg)分部持续增加市场份额,内窥镜业务和泌尿科业务表现良好 [2] - 神经调节业务的疼痛业务持续增长,得益于脊髓刺激系统(SCS)的创新产品组合 [3] - 公司在欧洲、中东和非洲(EMEA)地区也在成功拓展业务,多个业务部门表现良好 [6] 宏观经济环境挑战 - 地缘政治压力、供应链和劳动力市场的中断,给公司的盈利能力带来压力 [7][8]

Goodboy Picture Company/E+ via Getty ImagesBoston Scientific (NYSE:BSX) is set to report its second-quarter earnings on July 24. Expectations are high for this medical technologies giant following what has been an impressive share price rally in the first half of 2024. The stock is up 35% year-to-date, well ahead of healthcare sector benchmarks. We last covered BSX ahead of its first quarter report back in April highlighting the company's financial momentum, with new product launches driving a growth re ...

文章核心观点 - 波士顿科学公司（BSX）即将发布的季度财报预计将显示收入和盈利同比增加，但实际结果与市场预期的对比将显著影响其股价[1][2] 预期财务数据 - 公司预计季度每股收益为$0.58，同比增长9.4%[4] - 预计季度收入为$40.2亿美元，同比增长11.7%[4] 预期调整趋势 - 过去30天内，季度共识每股收益估计保持不变，反映出覆盖分析师在此期间对初始估计的重新评估[5] 盈利预期与实际对比 - 公司最近一个季度的实际每股收益为$0.56，超出预期$0.51，实现9.80%的意外增长[15] - 在过去四个季度中，公司四次超出共识每股收益估计[15] 盈利ESP分析 - 公司的盈利ESP为-1.72%，表明最准确的估计低于共识估计，分析师近期对公司盈利前景持悲观态度[12] - 公司目前持有Zacks排名2，这使得预测其是否能超出共识每股收益估计变得困难[12][13] 结论 - 尽管盈利超出预期可能增加股票成功的几率，但其他因素也可能影响股价，如未预见的催化剂或投资者的失望[16][17] - 波士顿科学公司目前不是一个明显的盈利超出候选者，投资者应关注其他因素以决定是否投资[18]

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Boston Scientific (BSX) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Boston Scientific is one of 1025 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different ...

Boston Scientific (BSX) closed at $78.02 in the latest trading session, marking a +0.42% move from the prior day. This move outpaced the S&P 500's daily gain of 0.28%. On the other hand, the Dow registered a gain of 0.53%, and the technology-centric Nasdaq increased by 0.4%.The the stock of medical device manufacturer has risen by 1.21% in the past month, leading the Medical sector's gain of 0.79% and undershooting the S&P 500's gain of 3.78%.Analysts and investors alike will be keeping a close eye on the p ...

MARLBOROUGH, Mass., July 1, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2024, on Wednesday, July 24, 2024, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will issue a news release announcing financial results for the second quarter on Ju ...

LAS VEGAS, NEVADA - JANUARY 10: An Abbott logo is displayed at the company's booth during CES 2024 ... [+] at the Las Vegas Convention Center on January 10, 2024 in Las Vegas, Nevada. CES, the world's largest annual consumer technology trade show, runs through January 12 and features about 4,000 exhibitors showing off their latest products and services to more than 130,000 attendees. (Photo by Ethan Miller/Getty Images)Getty ImagesAbbott stock (NYSE: ABT) currently trades at $105 per share, 25% below its pe ...

文章核心观点 - 公司股价在最新交易中小幅上涨0.01%,表现优于同期S&P 500指数下跌0.41% [1] - 公司过去一个月股价上涨2.67%,领先医疗行业1.74%的涨幅,但低于S&P 500指数3.53%的涨幅 [2] - 公司即将公布的季度财报预计每股收益将同比增长9.43%,收入同比增长11.68% [3] - 全年来看,公司每股收益和收入预计将分别同比增长13.17%和12.3% [4] 公司相关 - 分析师对公司业务表现和盈利能力持乐观态度,上调了公司业绩预测 [5][6] - 公司当前的Zacks评级为3级(持有) [7] - 公司估值方面,其市盈率高于行业平均水平,PEG率也高于行业平均 [8][9] 行业相关 - 公司所属的医疗器械行业目前在250多个行业中排名靠后,位于底部41% [10][11] - 历史数据显示,排名靠前的行业整体表现优于排名靠后的行业 [11]

Boston Scientific, Inc. (BSX) recently obtained a CE Mark on the Vercise Neural Navigator 5 Software with STIMVIEW XT technology. When used as an element of the Vercise Genus Deep Brain Stimulation (DBS) Systems, it can provide clinicians with simple and actionable data for efficient programming to treat Parkinson’s disease, essential tremor and dystonia.The latest development comes as a significant boost for the company’s Neuromodulation business. In July 2023, the software had received the FDA’s approval. ...

文章核心观点 - 美国股市在6月创下历史新高,主要指数连续创出新高 [1] - 人工智能(AI)相关股票如英伟达、微软和苹果等市值最高的公司表现强劲 [2] - 交易者的看涨押注创下历史新高,尤其是那些今年表现最佳的大型科技股 [3][4] 根据相关目录分别进行总结 新兴公司表现亮眼 - 家庭安全应用Life360(LIF)上市后股价稳步上涨,目前每股31.21美元 [6] - 分析师对Life360给予积极评级,11家分析师给予买入评级,平均目标价为52.07美元,较当前价格上涨67% [7] - Life360拥有6600万活跃用户,新上市公司表现强劲 [9] 医疗行业龙头表现稳健 - 波士顿科学(BSX)是医疗器械行业知名企业,开发了广泛应用的Taxus支架 [10] - 由于心脏病是美国主要死因,波士顿科学预计将持续增长 [11] - 波士顿科学最近收购了Silk Road Medical,股价创新高,市盈率达65.3倍 [12] - 分析师预计波士顿科学未来仍有上涨空间,目标价82.93美元,较当前价格上涨6.7% [13] 安全认证公司前景看好 - 科雷恩NXT(CXT)提供微光学安全产品和货币防伪解决方案 [14] - 公司最近收购OpSec Security以增强在线保护和产品认证业务 [15] - 公司任命新的支付业务负责人,该业务占总收入的三分之二,股价创新高 [16] - 尽管今年已涨14%,但CXT股票市盈率仅20倍,与同行业相当 [17] - 分析师给予强烈买入评级,目标价98.20美元,较当前价格上涨52% [18]